<DOC>
	<DOCNO>NCT02784106</DOCNO>
	<brief_summary>M2951 investigational drug evaluation treatment autoimmune inflammatory disorder . The purpose study assess efficacy M2951 subject rheumatoid arthritis ( RA ) currently treat stable dose methotrexate ( MTX ) .</brief_summary>
	<brief_title>Safety Efficacy Study M2951 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Men woman 18 75 year age time inform consent signature Confirmed diagnosis RA accord 2010 American College Rheumatology ( ACR ) /The European League Against Rheumatism ( EULAR ) RA classification criterion least 6 month duration Positive RF and/or antiCCP ( anticyclic citrullinated peptide ) Persistently active disease define great equal ( &gt; = ) 6 swollen joint ( 66 count ) &gt; = 6 tender joint ( 68 count ) Highsensitivity Creactive protein ( hsCRP ) &gt; = 3.6 milligram per liter ( mg/L ) Treatment &gt; = 12 week 10 25 mg/week MTX stable dose least 4 week prior dose investigational medicinal product ( IMP ) maintain throughout trial Women childbearing potential must use acceptable method contraception 4 week prior randomization , throughout trial , 90 day last dose IMP . For purpose trial Females postmenopausal ( agerelated amenorrhea &gt; = 12 consecutive month increase folliclestimulating hormone [ FSH ] great ( &gt; ) 40 milli international unit per milliliter [ mIU/mL ] ) , undergone hysterectomy bilateral oophorectomy exempt pregnancy test . If necessary confirm postmenopausal status , FSH drawn Screening Acceptable contraception define use either 2 barrier method ( eg , female diaphragm male condom ) , 1 barrier method conjunction one following : spermicide , intrauterine device , hormonal contraceptive ( implant oral ) Women childbearing potential must negative serum pregnancy test Screening Visit negative urine pregnancy test Day 1/randomization dosing . Use oral corticosteroid &gt; 10 mg daily prednisone equivalent , use injectable corticosteroid , change dose corticosteroid within 2 week prior Screening Screening Initiation change dose nonsteroidal antiinflammatory drug ( NSAIDs ) within 2 week prior Screening Treatment tofacitinib , Bruton 's Tyrosine Kinase ( BTK ) inhibitor , biologic diseasemodifying antirheumatic drug ( DMARD ; eg , antitumor necrosis factor alpha [ antiTNFÎ± ] , tocilizumab [ antiinterleukin6 receptor ] , abatacept [ CTLA4Fc ] ) , immunosuppressive drug ( sulfasalazine would acceptable stable dose ) methotrexate within 3 month prior Screening Screening Treatment antiCD20 therapy ( eg , rituximab ) within 12 month prior Screening Screening Immunologic disorder Rheumatoid Arthritis ( RA ) , exception secondary Sjogren 's syndrome associate RA , wellcontrolled diabetes thyroid disorder , condition require oral , intravenous , intramuscular , intraarticular corticosteroid therapy Vaccination live liveattenuated virus vaccine within 1 month prior Screening Active , clinically significant , viral , bacterial , fungal infection , major episode infection require hospitalization treatment parenteral antiinfectives within 4 week Screening Screening , completion oral antiinfectives within 2 week Screening , history recurrent infection ( ie , 3 type infection 12month rolling period ) . Vaginal candidiasis , onychomycosis , genital oral herpes simplex virus consider Investigator sufficiently control would exclusionary History positive test human immunodeficiency virus ( HIV ) , hepatitis C antibody and/or polymerase chain reaction , hepatitis B surface antigen ( HBsAg ) ( + ) and/or hepatitis B core total , and/or IgM antibody ( + ) Screening History current diagnosis active tuberculosis ( TB ) ; undergo treatment latent TB infection ( LTBI ) ; untreated LTBI ( determine document result within 3 month Screening Visit positive TB skin test purify protein derivative induration &gt; = 5 millimeter ( mm ) , positive QuantiFERONTB test positive borderline TSPOT [ Elispot ] test ) ; positive QuantiFERONTB test Screening . Subjects document complete appropriate LTBI treatment would exclude require tested Subjects current household contact active TB also exclude Indeterminate QuantiFERONTB TSPOT test may repeat , consider positive retest result positive indeterminate History cancer , except adequately treat basal cell squamous cell carcinoma skin ( 3 lesion require treatment lifetime ) carcinoma situ/cervical intraepithelial neoplasia uterine cervix , unless consider cure &gt; 5 year Clinically significant abnormality electrocardiogram ( ECG ) , active infective process clinically significant abnormality Screening chest Xray ( CXR ) take within 4 week first dose , per Investigator opinion . If CXR take within previous 3 month result available normal , CXR need carry B cell ( CD19 ) count le ( &lt; ) 50 % low limit normal Screening Significant cytopenia include absolute neutrophil count &lt; 1,500/ mm^3 , platelet count &lt; 100,000/mm^3 , absolute lymphocyte count &lt; 1,000/mm^3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>M2951</keyword>
	<keyword>Bruton 's Tyrosine Kinase ( BTK )</keyword>
</DOC>